MedTrace Logo

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

NCT02630030 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-03-26

Study results available
· View outcomes & findings →

Summary

This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has spread or returned after period of improvement who are planning to undergo surgery. When given by mouth, ixazomib may be able to reach tumor cells in the brain. Studying samples of tissue, blood, and plasma in the laboratory from patients receiving ixazomib may help doctors learn more about the effects of ixazomib on the cells. It may also help doctors understand how well patients will respond to treatment.

Conditions

Interventions

DRUG

Ixazomib

Given PO

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Jeffrey J. Olson, MD · Emory University/Winship Cancer Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-24
Primary Completion
2018-07-01
Completion
2020-09-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02630030 on ClinicalTrials.gov